[{"address1": "2617 Bissonnet Street", "address2": "Suite 225", "city": "Houston", "state": "TX", "zip": "77005", "country": "United States", "phone": "346 355 4099", "website": "https://www.alaunos.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.", "fullTimeEmployees": 1, "companyOfficers": [{"maxAge": 1, "name": "Mr. Dale Curtis Hogue Jr.", "age": 54, "title": "Interim CEO & Director", "yearBorn": 1970, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Melinda  Lackey", "age": 47, "title": "Senior VP of Legal, Administration & Secretary", "yearBorn": 1977, "fiscalYear": 2023, "totalPay": 625117, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 6, "compensationRisk": 9, "shareHolderRightsRisk": 3, "overallRisk": 7, "governanceEpochDate": 1738368000, "compensationAsOfEpochDate": 1703980800, "irWebsite": "http://ir.ziopharm.com/index.cfm", "maxAge": 86400, "priceHint": 4, "previousClose": 1.62, "open": 1.5932, "dayLow": 1.5932, "dayHigh": 1.62, "regularMarketPreviousClose": 1.62, "regularMarketOpen": 1.5932, "regularMarketDayLow": 1.5932, "regularMarketDayHigh": 1.62, "beta": -0.402, "forwardPE": -2.6999998, "volume": 5650, "regularMarketVolume": 5650, "averageVolume": 26554, "averageVolume10days": 11070, "averageDailyVolume10Day": 11070, "bid": 1.36, "ask": 1.85, "bidSize": 100, "askSize": 100, "marketCap": 2594025, "fiftyTwoWeekLow": 1.5, "fiftyTwoWeekHigh": 26.0, "priceToSalesTrailing12Months": 370.575, "fiftyDayAverage": 1.881, "twoHundredDayAverage": 4.4007, "currency": "USD", "enterpriseValue": 911028, "floatShares": 1433681, "sharesOutstanding": 1601250, "sharesShort": 65738, "sharesShortPriorMonth": 108490, "sharesShortPreviousMonthDate": 1735603200, "dateShortInterest": 1738281600, "sharesPercentSharesOut": 0.041100003, "heldPercentInsiders": 0.14109999, "heldPercentInstitutions": 0.10439, "shortRatio": 3.08, "shortPercentOfFloat": 0.0477, "impliedSharesOutstanding": 1601250, "bookValue": 1.701, "priceToBook": 0.95238096, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -11780000, "trailingEps": -315.39, "forwardEps": -0.6, "lastSplitFactor": "1:10", "lastSplitDate": 1721260800, "enterpriseToRevenue": 130.147, "enterpriseToEbitda": -0.127, "52WeekChange": -0.8948052, "SandP52WeekChange": 0.22903383, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "TCRT", "underlyingSymbol": "TCRT", "shortName": "Alaunos Therapeutics, Inc.", "longName": "Alaunos Therapeutics, Inc.", "firstTradeDateEpochUtc": 1124890200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "05ce1922-a43a-368b-a87c-0906e2ee068e", "messageBoardId": "finmb_11686323", "gmtOffSetMilliseconds": -18000000, "currentPrice": 1.62, "recommendationKey": "none", "totalCash": 1683000, "totalCashPerShare": 1.051, "ebitda": -7173000, "quickRatio": 2.038, "currentRatio": 4.298, "totalRevenue": 7000, "revenuePerShare": 0.004, "returnOnAssets": -0.40327, "returnOnEquity": -1.4172301, "grossProfits": -1374000, "freeCashflow": -8272625, "operatingCashflow": -11764000, "operatingMargins": -1059.5714, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-02-15"}]